Painreform is trading 6.5% down at $1.00 today, extending a multi-day slide following several prior sessions of steady declines.
- There are no fresh company-specific announcements, FDA updates, earnings, or analyst actions reported to account for the move.
- The decline appears to be driven by normal volatility for the thinly traded micro-cap biotech against a broader weak biotech tape and risk-off macro backdrop.